Oncolytic Virotherapy for Hematological Malignancies by Swarna Bais, Eric Bartee, Masmudur M. Rahman, Grant McFadden, Christopher R. Cogle

“…Ex vivo manipulations of the autograft to purge cancer cells using chemotherapies and toxins have been attempted. Because these past strategies lack specificity for malignant cells and often impair the normal hematopoietic stem and progenitor cells, prior efforts to ex vivo purge autografts have resulted in prolonged cytopenias and graft failure. …”
Get full text

Oral Capecitabine Achieves Response in Metastatic Eccrine Carcinoma by Kristian Larson, Hani M. Babiker, Andrew Kovoor, Joy Liau, Jordan Eldersveld, Emad Elquza

“…The disease responded poorly to taxane- and platinum-based chemotherapies as well as an isolated limb perfusion of an alkylating agent. …”
Get full text

Resolution of Crizotinib-Associated Fulminant Hepatitis following Cessation of Treatment by Gregory W. Charville, Sukhmani K. Padda, Richard K. Sibley, Ajithkumar Puthillath, Paul Y. Kwo

“…Targeted cancer treatments offer the prospect of precise inhibition of tumor growth without the untoward off-target toxicity of traditional chemotherapies. Still, unintended, often idiosyncratic side effects, such as drug-induced liver injury, can occur. …”
Get full text

Employing the Oncolytic Vesicular Stomatitis Virus in Cancer Virotherapy: Resistance and Clinical Considerations by Alaa A. Abdelmageed, Stephen Dewhurst, Maureen C. Ferran

“…Strategies to overcome resistance include enhancing viral oncoselectivity, inhibiting IFN responses, modulating the TME, and combining VSV with chemotherapies, radiation, and immune checkpoint inhibitors. …”
Get full text

Identifying common pathways for doxorubicin and carfilzomib-induced cardiotoxicities: transcriptomic and epigenetic profiling by Conagh Kelly, Dylan J. Kiltschewskij, Angeline J.W. Leong, Tatt Jhong Haw, Amanda J. Croft, Lohis Balachandran, Dongqing Chen, Danielle R. Bond, Heather J. Lee, Murray J. Cairns, Aaron L. Sverdlov, Doan T. M. Ngo

“…Given this common cardiotoxic effect of these chemotherapies, we aimed to investigate differential and common mechanism(s) associated with Doxorubicin and Carfilzomib-induced cardiac dysfunction. …”
Get full text

TRIM25: A Global Player of Cell Death Pathways and Promising Target of Tumor-Sensitizing Therapies by Wolfgang Eberhardt, Usman Nasrullah, Josef Pfeilschifter

“…A better understanding of the complex repertoire of cell death modulatory effects by TRIM25 is an essential prerequisite for validating TRIM25 as a potential target for future anticancer therapy to surmount the high failure rate of currently used chemotherapies.…”
Get full text

Evaluation of Anti-Cancer, Pro-Apoptotic, and Anti-Metastatic Effects of Synthetic Analogue Compound 2-Imino-7-Methoxy-4-(4-fluorophenyl)-2H-1,3-Thiazino [3,2-a] Benzimidazole on P... by Mpho Ndou, Marthe C. D. Fotsing, Michael H. K. Kengne, Edwin M. Mmutlane, Derek T. Ndinteh, Mthokozisi B.C. Simelane, Lesetja Motadi, Mpho Choene

“… Synthetic compounds are widely used in cancer drug discovery. Chemotherapies aim to inhibit proliferation and induce apoptosis however, they have limitations. …”
Get full text

Wnt5a Increases Properties of Lung Cancer Stem Cells and Resistance to Cisplatin through Activation of Wnt5a/PKC Signaling Pathway by Jiali Yang, Kangjian Zhang, Jing Wu, Juan Shi, Jing Xue, Jing Li, Juan Chen, Yongzhao Zhu, Jun Wei, Jinxi He, Xiaoming Liu

“…These data thus suggested that the Wnt5a could promote lung cancer cell mobility and cisplatin-resistance through a Wnt/PKC signaling pathway and a blockage of this signaling may be an alternative therapeutic strategy for NSCLC patients with resistance to chemotherapies.…”
Get full text

Cost Effectiveness Analysis of Eribulin Mesylate as a Treatment for Metastatic Breast Cancer in Spain: Management in the Later Line of Therapy by Gabriel Tremblay, Unnati Majethia, Ilias Kontoudis, Jesús De Rosendo

“…Model inputs were overall survival, progression-free survival and costs relating to chemotherapies, grade 3/4 adverse events and healthcare utilization. …”
Get full text

A central role for Foxp3+ regulatory T cells in K-Ras-driven lung tumorigenesis. by Courtney A Granville, Regan M Memmott, Andria Balogh, Jacopo Mariotti, Shigeru Kawabata, Wei Han, Jaclyn Lopiccolo, Jason Foley, David J Liewehr, Seth M Steinberg, Daniel H Fowler, M Christine Hollander, Phillip A Dennis

“…Because these mutations confer resistance to commonly used cytotoxic chemotherapies and targeted agents, effective therapies that target K-Ras are needed. …”
Get full text

Revisiting ABC Transporters and Their Clinical Significance in Glioblastoma by Brandon Wee Siang Phon, Shalini Sundramurthi Chelliah, Dina El-Rabie Osman, Saatheeyavaane Bhuvanendran, Ammu Kutty Radhakrishnan, Muhamad Noor Alfarizal Kamarudin

“…<b>Background</b>: The multiple drug-resistant phenomenon has long since plagued the effectiveness of various chemotherapies used in the treatment of patients with glioblastoma (GBM), which is still incurable to this day. …”
Get full text

An anoikis-related signature predicts prognosis and immunotherapy response in gastrointestinal cancers by Ruyi Liu, Ruyi Liu, Ruyi Liu, Ruyi Liu, Ruyi Liu, Yuchen Liu, Yuchen Liu, Yuchen Liu, Yuchen Liu, Yuchen Liu, Weicheng Huang, Weicheng Huang, Weicheng Huang, Weicheng Huang, Weicheng Huang, Pengxiang Chen, Pengxiang Chen, Pengxiang Chen, Pengxiang Chen, Pengxiang Chen, Yufeng Cheng, Yufeng Cheng, Yufeng Cheng, Yufeng Cheng, Yufeng Cheng

“…The drug sensitivity analysis revealed that patients with high or low Anoscores were sensitive to different chemotherapies and targeted drugs. S100A11 and TLR3, representative candidate genes, exhibited different expression patterns and biological functions.ConclusionThis study highlighted the significant potential of the Anoscore in predicting prognosis and guiding the selection of personalized therapeutic regimens for patients with GI cancers.…”
Get full text